Caplin Point Laboratories Limited (NSE: CAPLIPOINT) experiences a 5% intraday decline to ₹2493.9, breaking below its support line in the Healthcare sector.
Caplin Point Laboratories Limited (NSE: CAPLIPOINT) stock gains 5% intraday to ₹2601.2, showing a bounce despite a breakdown trendline status.
Caplin Point Laboratories Limited (NSE: CAPLIPOINT) shows pressure after breakout, moving down 5% intraday to ₹2477.7.
Caplin Point Laboratories Limited (CAPLIPOINT) secures USFDA approval for Foscarnet Sodium Injection, a significant milestone for its subsidiary Caplin Steriles.